Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial.
Saved in:
| Title: | Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. |
|---|---|
| Authors: | Long, Georgina V1,2 (AUTHOR) georgina.long@sydney.edu.au, Saw, Robyn P M1,3 (AUTHOR), Lo, Serigne1 (AUTHOR), Nieweg, Omgo E1,3 (AUTHOR), Shannon, Kerwin F1,3 (AUTHOR), Gonzalez, Maria1 (AUTHOR), Guminski, Alexander1,2 (AUTHOR), Lee, Jenny H1,4 (AUTHOR), Lee, Hansol1 (AUTHOR), Ferguson, Peter M1,3 (AUTHOR), Rawson, Robert V1,3 (AUTHOR), Wilmott, James S1 (AUTHOR), Thompson, John F1,3 (AUTHOR), Kefford, Richard F1,4 (AUTHOR), Ch'ng, Sydney1,3 (AUTHOR), Stretch, Jonathan R1,3 (AUTHOR), Emmett, Louise5 (AUTHOR), Kapoor, Rony6 (AUTHOR), Rizos, Helen1,4 (AUTHOR), Spillane, Andrew J1,2 (AUTHOR) |
| Source: | Lancet Oncology. Jul2019, Vol. 20 Issue 7, p961-971. 11p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
